However, the PFS differed after EGFR-TKIs therapy given as first-line or second/higher-line therapy (P = 0.04), suggesting that the timing of EGFR-TKI use affected PFS in advanced EGFR-mutant NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.